Get the Stockscreener App
27.57
2.80%
0.75
Uniqure Nv stock is traded at $27.57, with a volume of 835.52K.
It is up +2.80% in the last 24 hours and down -5.26% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
See More
Previous Close:
$26.82
Open:
$26.87
24h Volume:
835.52K
Relative Volume:
0.47
Market Cap:
$1.74B
Revenue:
$18.09M
Net Income/Loss:
$-208.87M
P/E Ratio:
-7.8491
EPS:
-3.5125
Net Cash Flow:
$-178.15M
1W Performance:
+4.23%
1M Performance:
-5.26%
6M Performance:
+41.31%
1Y Performance:
+72.42%
1-Day Range:
$26.80
$28.71
1-Week Range:
$25.65
$28.71
52-Week Range:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Name
Uniqure Nv
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
27.57 | 1.74B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Mizuho | Neutral → Outperform |
| Mar-09-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-03-26 | Downgrade | Mizuho | Outperform → Neutral |
| Mar-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure Nv Stock (QURE) Latest News
RSU grant, options and tax sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (QURE) director trades shares, receives RSUs and stock options - Stock Titan
Tax-related share sale by uniQure (NASDAQ: QURE) chief customer officer - Stock Titan
uniQure (QURE) director receives RSUs, stock options and sells shares for taxes - Stock Titan
uniQure (QURE) director Leonard Post awarded RSUs, options and sells shares for taxes - Stock Titan
Director Jack Kaye at uniQure (QURE) gets RSUs and options, sells shares for taxes - Stock Titan
Equity awards and tax-driven share sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (NASDAQ: QURE) director awarded RSUs, sells shares for taxes - Stock Titan
What Caused uniQure's Dramatic Stock Plunge - Kavout
[144] uniQure N.V. SEC Filing - Stock Titan
UniQure (NASDAQ: QURE) reports 7,970 RSUs vest and 10,000-share 10b5-1 sale - Stock Titan
UniQure N.V. (QURE) files Rule 144 to sell 7,970 RSU shares on 06/11/2026 - Stock Titan
Jack Kaye sale notice at UniQure (NASDAQ: QURE) — 7,970 shares proposed - Stock Titan
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Trading the Move, Not the Narrative: (QURE) Edition - Stock Traders Daily
Fiera Capital Corp Invests $18.39 Million in uniQure N.V. $QURE - MarketBeat
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
What Just Happened with uniQure's Earnings and FDA Update - Kavout
QURE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesWeak Earnings Momentum - newsline.com
Director Kaye trades uniQure (QURE) shares in 10b5-1 option exercise and sale - Stock Titan
Huntingtons Disease Market Size to Hit USD 6.48 Billion by 2035 - Precedence Research
Mizuho downgrades UniQure NV (QURE) - MSN
Form 144 uniQure N.V. For: 3 June By Investing.com - Investing.com South Africa
uniQure: Why A Shifting FDA Could Change Everything For AMT-130 (NASDAQ:QURE) - Seeking Alpha
Tracing UniQure's Tale Of Boom, Bust, And Rebound - RTTNews
(QURE) Volatility Zones as Tactical Triggers - Stock Traders Daily
uniQure stock surges 20% on Replimune FDA BLA news By Investing.com - Investing.com Australia
uniQure stock surges 20% on Replimune FDA BLA news - Investing.com
QURE News | UNIQURE NV (NASDAQ:QURE) - ChartMill
uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati - AD HOC NEWS
uniQure Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue, Stock SlipsCapex Guidance - newsline.com
Numero AI and Royu Merge to Redefine How Finance Teams Operate - Benzinga
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Insider Monkey
Uniqure NV at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
uniQure N.V. (QURE) Stalls at $24.84 — Breakout or Breakdown? 2026-05-19PCR Moving Average - newsline.com
Price-Driven Insight from (QURE) for Rule-Based Strategy - Stock Traders Daily
Huntington's Disease Pipeline 2026: Therapies Under - openPR.com
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
Mizuho maintains uniQure NV (QURE) outperform recommendation - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
UBS Group AG Buys 286,465 Shares of uniQure N.V. $QURE - MarketBeat
Uniqure Nv Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure Nv Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Jun 10 '26 |
Option Exercise |
16.04 |
2,645 |
42,426 |
34,987 |
| Gut Robert | Director |
Jun 10 '26 |
Sale |
26.05 |
7,552 |
196,720 |
27,435 |
| Gut Robert | Director |
Jun 11 '26 |
Sale |
27.06 |
2,726 |
73,766 |
32,259 |
| O'Keefe Kylie | Chief Customer & Strat Officer |
Jun 11 '26 |
Sale |
27.06 |
15,936 |
431,228 |
108,864 |
| Springhorn Jeremy P. | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
43,251 |
| POST LEONARD E | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
35,494 |
| Kaye Jack | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
25,996 |
| Jacques Rachelle Suzanne | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
33,903 |
| Balachandran Madhavan | Director |
Jun 11 '26 |
Sale |
27.06 |
1,993 |
53,931 |
43,254 |
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):